Trial Profile
Open-label study to assess safety and efficacy of a single dose (i.v.) of NMK36 in subjects with brain tumor
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Fluciclovine 18F (Primary)
- Indications Glioma
- Focus Adverse reactions; Diagnostic use
- Sponsors Nihon Medi-Physics
- 20 Jan 2016 New trial record